Pharmacological treatment of osteoporosis in the oldest old

References

• CosmanFde BeurSJLeBoffMSClinician’s guide to prevention and treatment of osteoporosisOsteoporos Int201425102359238125182228
   PubMed Web of Science ®Google Scholar
• CooperCCampionGMeltonLJHip fractures in the elderly: a worldwide projectionOsteoporosis Int199226285289
   PubMed Web of Science ®Google Scholar
• GradosFMarcelliCDargent-MolinaPPrevalence of vertebral fractures in French women older than 75 years from the EPIDOS studyBone200434236236714962815
   PubMed Web of Science ®Google Scholar
• NguyenTVCenterJRSambrookPNEismanJARisk factors for proximal humerus, forearm, and wrist fractures in elderly men and women: the Dubbo Osteoporosis Epidemiology StudyAm J Epidemiol2001153658759511257067
   PubMed Web of Science ®Google Scholar
• SeemanEBoonenSBorgstromFFive years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of ageBone20104641038104220026265
   PubMed Web of Science ®Google Scholar
• SambrookPCooperCOsteoporosisLancet200636795272010201816782492
   PubMed Web of Science ®Google Scholar
• KanisJABorgstromFCompstonJSCOPE: a scorecard for osteoporosis in EuropeArch Osteoporos2013814424030479
   PubMed Web of Science ®Google Scholar
• GielenEVerschuerenSO’NeillTWMusculoskeletal frailty: a geriatric syndrome at the core of fracture occurrence in older ageCalcif Tissue Int201291316117722797855
   PubMed Web of Science ®Google Scholar
• BoonenSAutierPBaretteMVanderschuerenDLipsPHaentjensPFunctional outcome and quality of life following hip fracture in elderly women: a prospective controlled studyOsteoporos Int2004152879414605799
   PubMed Web of Science ®Google Scholar
• LeibsonCLTostesonANGabrielSERansomJEMeltonLJMortality, disability, and nursing home use for persons with and without hip fracture: a population-based studyJ Am Geriatr Soc200250101644165012366617
   PubMed Web of Science ®Google Scholar
• SchnellSFriedmanSMMendelsonDABinghamKWKatesSLThe 1-year mortality of patients treated in a hip fracture program for eldersGeriatr Orthop Surg Rehabil20101161423569656
   PubMedGoogle Scholar
• International Osteoporosis Foundation [webpage on the Internet]Facts and statistics Available from: https://www.iofbonehealth.org/facts-statisticsAccessed December 1, 2016
   Google Scholar
• GielenEVanderschuerenDCallewaertFBoonenSOsteoporosis in menBest Prac Res Clin Endocrinol Metab2011252321335
   Web of Science ®Google Scholar
• HaentjensPMagazinerJColon-EmericCSMeta-analysis: excess mortality after hip fracture among older women and menAnn Intern Med2010152638039020231569
   PubMed Web of Science ®Google Scholar
• FeldsteinAElmerPJOrwollEHersonMHillierTBone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementationArch Intern Med2003163182165217214557214
   PubMed Web of Science ®Google Scholar
• RosenCJAbramsSAAloiaJFIOM committee members respond to Endocrine Society vitamin D guidelineJ Clin Endocrinol Metab20129741146115222442278
   PubMed Web of Science ®Google Scholar
• LipsPVitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implicationsEndocr Rev200122447750111493580
   PubMed Web of Science ®Google Scholar
• HolickMFMatsuokaLYWortsmanJAge, vitamin D, and solar ultravioletLancet19892867111041105
   PubMed Web of Science ®Google Scholar
• MithalAWahlDABonjourJPGlobal vitamin D status and determinants of hypovitaminosis DOsteoporos Int200920111807182019543765
   PubMed Web of Science ®Google Scholar
• KuchukNOPluijmSMvan SchoorNMLoomanCWSmitJHLipsPRelationships of serum 25-hydroxyvitamin D to bone mineral density and serum parathyroid hormone and markers of bone turnover in older personsJ Clin Endocrinol Metab20099441244125019158198
   PubMed Web of Science ®Google Scholar
• BeaudartCBuckinxFRabendaVThe effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trialsJ Clin Endocrinol Metab201499114336434525033068
   PubMed Web of Science ®Google Scholar
• Dawson-HughesBMithalABonjourJPIOF position statement: vitamin D recommendations for older adultsOsteoporos Int20102171151115420422154
   PubMed Web of Science ®Google Scholar
• BouillonRVan SchoorNMGielenEOptimal vitamin D status: a critical analysis on the basis of evidence-based medicineJ Clin Endocrinol Metab2013988E1283E130423922354
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society Workgroup on Vitamin D Supplementation for Older AdultsRecommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for prevention of falls and their consequencesJ Am Geriatr Soc201462114715224350602
   PubMed Web of Science ®Google Scholar
• LappeJMBinkleyNVitamin D and Sarcopenia/FallsJ Clin Densitom201518447848226059567
   PubMed Web of Science ®Google Scholar
• Bischoff-FerrariHADawson-HughesBPlatzAEffect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trialArch Intern Med2010170981382020458090
   PubMedGoogle Scholar
• Bischoff-FerrariHADawson-HughesBOravEJMonthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trialJAMA Intern Med2016176217518326747333
   PubMed Web of Science ®Google Scholar
• RossACMansonJEAbramsSAThe 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to knowJ Clin Endocrinol Metab2011961535821118827
   PubMed Web of Science ®Google Scholar
• Institute of MedicineDietary Reference Intakes for Calcium and Vitamin DWashington, DCThe National Academies Press2011
   Google Scholar
• HolickMFBinkleyNCBischoff-FerrariHAEvaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guidelineJ Clin Endocrinol Metab20119671911193021646368
   PubMed Web of Science ®Google Scholar
• BollandMJGreyAGambleGDReidIRThe effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysisLancet Diabetes Endocrinol20142430732024703049
   PubMed Web of Science ®Google Scholar
• Bischoff-FerrariHAOravEJWillettWCDawson-HughesBThe effect of vitamin D supplementation on skeletal, vascular, or cancer outcomesLancet Diabetes Endocrinol20142536336424795248
   PubMed Web of Science ®Google Scholar
• BoonenSLipsPBouillonRBischoff-FerrariHAVanderschuerenDHaentjensPNeed for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trialsJ Clin Endocrinol Metab20079241415142317264183
   PubMed Web of Science ®Google Scholar
• DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) GroupPatient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and EuropeBMJ2010340b546320068257
   PubMed Web of Science ®Google Scholar
• AvenellAGillespieWJGillespieLDO’ConnellDVitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosisCochrane Database Syst Rev20092CD000227
   Google Scholar
• JacksonCGaugrisSSenSSHoskingDThe effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysisQJM2007100418519217308327
   PubMed Web of Science ®Google Scholar
• JacksonRDLaCroixAZGassMCalcium plus vitamin D supplementation and the risk of fracturesN Engl J Med2006354766968316481635
   PubMed Web of Science ®Google Scholar
• GrantAMAvenellACampbellMKOral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trialLancet200536594711621162815885294
   PubMed Web of Science ®Google Scholar
• BoonenSVanderschuerenDHaentjensPLipsPCalcium and vitamin D in the prevention and treatment of osteoporosis – a clinical updateJ Intern Med2006259653955216704554
   PubMed Web of Science ®Google Scholar
• BollandMJAvenellABaronJAEffect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysisBMJ2010341c369120671013
   PubMed Web of Science ®Google Scholar
• BollandMJGreyAAvenellAGambleGDReidIRCalcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysisBMJ2011342d204021505219
   PubMed Web of Science ®Google Scholar
• VerbruggeFGielenEMilisenKBoonenSWho should receive calcium and vitamin D supplementation?Age Ageing201241557658022877606
   PubMed Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet19963489041153515418950879
   PubMed Web of Science ®Google Scholar
• CummingsSRBlackDMThompsonDEEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJAMA199828024207720829875874
   PubMed Web of Science ®Google Scholar
• BlackDMThompsonDEBauerDCFracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research GroupJ Clin Endocrinol Metab200085114118412411095442
   PubMed Web of Science ®Google Scholar
• EnsrudKEBlackDMPalermoLTreatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention TrialArch Int Med199715722261726249531231
   PubMed Web of Science ®Google Scholar
• HochbergMCThompsonDEBlackDMEffect of alendronate on the age-specific incidence of symptomatic osteoporotic fracturesJ Bone Miner Res200520697197615883637
   PubMed Web of Science ®Google Scholar
• AxelssonKLundhDLorentzonMAlendronate treatment is associated with reduced fracture risk and maintained safety in the oldest oldPoster presented at: ASBMR Annual Meeting2016Atlanta, GA
   Google Scholar
• HarrisSTWattsNBGenantHKEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study GroupJAMA1999282141344135210527181
   PubMed Web of Science ®Google Scholar
• ReginsterJMinneHWSorensenOHRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporos Int2000111839110663363
   PubMed Web of Science ®Google Scholar
• McClungMRGeusensPMillerPDEffect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study GroupN Engl J Med2001344533334011172164
   PubMed Web of Science ®Google Scholar
• BoonenSMcClungMREastellREl-Hajj FuleihanGBartonIPDelmasPSafety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest oldJ Am Geriatr Soc200452111832183915507059
   PubMed Web of Science ®Google Scholar
• TomSEAdachiJDAndersonFAJrFrailty and fracture, disability, and falls: a multiple country study from the global longitudinal study of osteoporosis in womenJ Am Geriatr Soc201361332733423351064
   PubMed Web of Science ®Google Scholar
• CryerBBauerDCOral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?Mayo Clin Proc200277101031104312374247
   PubMed Web of Science ®Google Scholar
• LoJCPressmanAROmarMAEttingerBPersistence with weekly alendronate therapy among postmenopausal womenOsteoporos Int200617692292816609824
   PubMed Web of Science ®Google Scholar
• BoonenSBlackDMColon-EmericCSEfficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and olderJ Am Geriatr Soc201058229229920070415
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellROnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
   PubMed Web of Science ®Google Scholar
• LylesKWColon-EmericCSMagazinerJSZoledronic acid in reducing clinical fracture and mortality after hip fractureN Engl J Med2007357181799180917878149
   PubMed Web of Science ®Google Scholar
• CummingsSRSan MartinJMcClungMRDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
   PubMed Web of Science ®Google Scholar
• BoonenSAdachiJDManZTreatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high riskJ Clin Endocrinol Metab20119661727173621411557
   PubMed Web of Science ®Google Scholar
• McClungMRBoonenSTorringOEffect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosisJ Bone Miner Res201227121121821976367
   PubMed Web of Science ®Google Scholar
• GenantHKLibanatiCEngelkeKImprovements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumabBone201356248248823871852
   PubMed Web of Science ®Google Scholar
• MeunierPJRouxCSeemanEThe effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosisN Engl J Med2004350545946814749454
   PubMed Web of Science ®Google Scholar
• ReginsterJYSeemanEDe VernejoulMCStrontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) studyJ Clin Endocrinol Metab20059052816282215728210
   PubMed Web of Science ®Google Scholar
• SeemanEVellasBBenhamouCStrontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and olderJ Bone Miner Res20062171113112016813532
   PubMed Web of Science ®Google Scholar
• NeerRMArnaudCDZanchettaJREffect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosisN Engl J Med2001344191434144111346808
   PubMed Web of Science ®Google Scholar
• BoonenSMarinFMellstromDSafety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspectiveJ Am Geriatr Soc200654578278916696744
   PubMed Web of Science ®Google Scholar
• RizzoliRReginsterJYBoonenSAdverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosisCalcif Tissue Int20118929110421637997
   PubMed Web of Science ®Google Scholar
• RizzoliRBrancoJBrandiMLManagement of osteoporosis of the oldest oldOsteoporos Int201425112507252925023900
   PubMed Web of Science ®Google Scholar
• InderjeethCAFooACLaiMMGlendenningPEfficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidenceBone200944574475119130909
   PubMed Web of Science ®Google Scholar
• VondracekSFLinneburSADiagnosis and management of osteoporosis in the older seniorClin Interv Aging2009412113619503775
   PubMed Web of Science ®Google Scholar
• LowAShould all elderly women receive bisphosphonates to prevent osteoporotic fractures?Can J Hosp Pharm2012651454822479113
   PubMedGoogle Scholar
• European Medicines AgencyZoledronic acid. Summary of product characteristics Available from: http://www.emea.europa.euAccessed December 1, 2016
   Google Scholar
• JamalSALjunggrenOStehman-BreenCEffects of denosumab on fracture and bone mineral density by level of kidney functionJ Bone Miner Res20112681829183521491487
   PubMed Web of Science ®Google Scholar
• FriedLPTangenCMWalstonJFrailty in older adults: evidence for a phenotypeJ Gerontol A Biol Sci Med Sci2001563M146M15611253156
   PubMed Web of Science ®Google Scholar
• RollandYAbellan Van KanGGillette-GuyonnetSRouxCBoonenSVellasBStrontium ranelate and risk of vertebral fractures in frail osteoporotic womenBone201148233233820817053
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyProtelos-H-C-560-PSU-31: EPAR-Assessment Report-Periodic safety update report2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000560/WC500147168.pdfAccessed February 15, 2017
   Google Scholar
• ReginsterJYCardiac concerns associated with strontium ranelateExpert Opin Drug Saf20141391209121325020233
   PubMed Web of Science ®Google Scholar